Lupus & antiphospholipid syndrome
Twelve-month follow-up after telitacicept withdrawal in patients with SLE: a single-centre study
Authors' conclusion
The majority of patients (37.5%) discontinued telitacicept due to achieving LLDAS. During the 12-month follow-up after drug withdrawal, 75% (30/40) of patients remained stable, whereas 25% had disease progression.
Study context
- Population
- SLE patients who discontinued telitacicept and were under long-term follow-up at Peking Union Medical College Hospital
- Participants
- 48 patients
- Outcome
- Reasons for telitacicept discontinuation and subsequent disease outcomes
- Follow-up
- 12 months
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Discontinued due to achieving lupus low disease activity state (LLDAS) (physician recommendation)
- 18 (37.5%, 18/48)
- Discontinued for disease status changes necessitating treatment adjustment
- 16.7%, 8/48
- Discontinued for decreased immunoglobulin G levels
- 6.2%, 3/48
- Discontinued for infection/fever
- 6.2%, 3/48
- Relatively stable SLEDAI scores over 12-month follow-up (40 patients without changes to concomitant therapies)
- 30 (75%)
- Increased SLEDAI scores over 12-month follow-up (40 patients without changes to concomitant therapies)
- 10 (25%)
Observational data: associations, not effects.
Further findings
Characteristics at withdrawal in patients with active disease after discontinuation
- High rate of central nervous system involvement
Serological markers · 12 months postdiscontinuation
- No significant fluctuations (p>0.05 for all comparisons)
Original publication
Twelve-month follow-up after telitacicept withdrawal in patients with SLE: a single-centre study. Lupus Sci Med. Published 18 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →